{"id":17830,"date":"2022-07-01T17:07:46","date_gmt":"2022-07-01T11:37:46","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17830"},"modified":"2023-01-02T09:36:28","modified_gmt":"2023-01-02T04:06:28","slug":"chlamydia-treatment-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook","title":{"rendered":"Chlamydia Treatment: Is it the End of the Antibiotic Era?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f6399320630\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f6399320630\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook\/#How_to_Circumvent_the_Challenges\" >How to Circumvent the Challenges?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook\/#Potential_Chlamydia_Treatment_Options_in_Development\" >Potential Chlamydia Treatment Options in Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook\/#Expected_Roadblocks\" >Expected Roadblocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook\/#Way_Ahead\" >Way Ahead<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Chlamydia is the most common bacterial sexually transmitted infection across the world. Chlamydia infection is asymptomatic in<strong> 50-88%<\/strong> of men and women, and <strong>46%<\/strong> of infections resolve spontaneously after a year. In women, persistent chlamydia infection can cause pelvic inflammatory disease, ectopic pregnancy, tubal infertility, and in men, epididymitis and epididymo-orchitis. Chlamydia infection can strike at any age, although it is most frequent in those under the age of 25, with rates of diagnosis increasing in women aged 16 to 19 and men aged 20 to 24.<\/p>\n\n\n\n<p><strong>Azithromycin <\/strong>has been considered the first-line treatment for chlamydia infection for many years. Recent research, however, suggests the emergence of azithromycin resistance due to its widespread use to treat infections. For chlamydia treatment, data from observational studies comparing azithromycin to doxycycline revealed that azithromycin had a greater chlamydia treatment failure rate than doxycycline. To combat resistance development, the CDC recently updated STI recommendations for managing chlamydia in 2021. According to these revised guidelines, the recommended therapy for chlamydia treatment is now <strong>doxycycline 100 mg <\/strong>twice daily orally for 7 days.<\/p>\n\n\n\n<p>The development of antibiotic resistance and the rise in infected cases have become a global threat. Over the past 10 years, the diagnosed cases of chlamydia infection have peaked due to more sensitive tests and increased chlamydia testing. As per DelveInsight\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-epidemiology-forecast\"><strong>Chlamydia Epidemiology Report<\/strong><\/a>, seven major markets accounted for more than <strong>3 million cases<\/strong> in 2021, and it is estimated that the cases will reach up to <strong>5 million<\/strong> by 2032. The United States contributed the highest cases among the seven major markets, while Italy accounted for the lowest in 2021.&nbsp;<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-76e5d547-3fb9-415f-b7fe-be310a21468a\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-rverrna-608-\"><rect fill=\"none\" height=\"292\" width=\"438\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-rverrna-613-\"><rect fill=\"none\" height=\"292\" width=\"438\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-rverrna-614-\"><rect fill=\"none\" height=\"292\" width=\"438\" x=\"61\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"292\" width=\"438\" x=\"61\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 170.5 71 L 170.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 279.5 71 L 279.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 389.5 71 L 389.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 71 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 60.5 71 L 60.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 61 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 290.5 L 499 290.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 217.5 L 499 217.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 144.5 L 499 144.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 70.5 L 499 70.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"292\" width=\"438\" x=\"61\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 61 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.40000009536743 217)\" x=\"26.40000009536743\" y=\"217\">Diagnosed Incident Cases in Million<\/text><path class=\"highcharts-axis-line\" d=\"M 61 71 L 61 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-rverrna-613-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(61,71) scale(1 1)\"><rect aria-label=\"7MM, 3.4. Diagnosed Incident Cases (in million).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"248\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"53\" x=\"27.5\" y=\"44.5\"><\/rect><rect aria-label=\"US, 1.9. Diagnosed Incident Cases (in million).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"139\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"53\" x=\"137.5\" y=\"153.5\"><\/rect><rect aria-label=\"EU5, 1.1. Diagnosed Incident Cases (in million).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"80\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"53\" x=\"246.5\" y=\"212.5\"><\/rect><rect aria-label=\"Japan, 0.32. Diagnosed Incident Cases (in million).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"23\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"53\" x=\"356.5\" y=\"269.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(61,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Chlamydia Epidemiological Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">Diagnosed Incident Cases of Chlamydia in 2021<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(61,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(40,21)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">3.4<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>3.4<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(150,130)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">1.9<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>1.9<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(259,189)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">1.1<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>1.1<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(365,246)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">0.32<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>0.32<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"115.75\" y=\"382\">7MM<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"225.25\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"334.75\" y=\"382\">EU5<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"444.25\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"294\">1<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"221\">2<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"148\">3<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"75\">4<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Chlamydia Epidemiology Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Chlamydia Epidemiology Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-rverrna-614-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Chlamydia Epidemiological Insights\"},\"subtitle\":{\"text\":\"Diagnosed Incident Cases of Chlamydia in 2021\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Diagnosed Incident Cases (in million)\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Diagnosed Incident Cases (in million)\\\"\\n\\\"7MM\\\";3.4\\n\\\"US\\\";1.9\\n\\\"EU5\\\";1.1\\n\\\"Japan\\\";0.32\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Diagnosed Incident Cases in Million\"}}],\"credits\":{\"text\":\"Chlamydia Epidemiology Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-epidemiology-forecast\"},\"legend\":{\"enabled\":false}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-76e5d547-3fb9-415f-b7fe-be310a21468a\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_to_Circumvent_the_Challenges\"><\/span><strong>How to Circumvent the Challenges?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Antimicrobial stewardship<\/strong> is a program that promotes the right use of antimicrobials in order to avoid resistance, which is one of the most serious public health issues in the United States. The revised updates were recommended because of concerns about higher rates of <strong>azithromycin and ceftriaxone<\/strong> resistance when taken at lower doses.<\/p>\n\n\n\n<p>Besides <strong>doxycycline<\/strong>&nbsp; <strong>100 mg <\/strong>twice daily for 7 days, other substitute regimens, either <strong>azithromycin 1 g<\/strong> orally in a single dose or <strong>levofloxacin 500 mg<\/strong> once daily for 7 days, are also recommended to subdue the development of antibiotic resistance. Notably, a delayed-release (DR) formulation of doxycycline is available on the market to reduce pill burden and alleviate gastrointestinal symptoms. <strong>Doxycycline 200 mg<\/strong> DR tablets should be used once a day for 7 days as part of this regimen. This formulation is as effective as the instant release formulation but is more expensive. Furthermore, <strong>Ofloxacin <\/strong>(but not all other quinolones) is also effective in chlamydia treatment. In general, <strong>erythromycin <\/strong>is regarded as a backup chlamydia medicine for those who are unable to follow another regimen.<\/p>\n\n\n\n<p>Furthermore, chlamydia screening is implemented in several countries and regions, including the US and the UK, to reduce the risks. Chlamydia screening is advised for all women under the age of 25, pregnant women, and those at high risk of infection.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Potential_Chlamydia_Treatment_Options_in_Development\"><\/span><strong>Potential Chlamydia Treatment Options in Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Chlamydia is one of the major bacterial pathogens that infect humans. Antibiotics are the only currently available chlamydia treatment option. However, there is mounting pressure to develop chlamydia vaccines with high reinfection rates. One of the most challenging aspects of <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/chlamydial-infection-newsletter\">chlamydia vaccine trials<\/a> research is replicating mouse vaccine trial results in other host species, specifically nonhuman primates. Over the last 30 years, limited attempts have been to replicate mouse model chlamydia vaccine trials results in nonhuman primates.<\/p>\n\n\n\n<p>Many key assets, including chlamydia vaccines, are at the preclinical stage of development. The major chlamydia companies such as <strong>Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris,<\/strong> <strong>Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax,<\/strong> and others are currently working to develop <a href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-pipeline-insight\"><strong>new drugs for chlamydia treatment<\/strong><\/a> which can be available in the chlamydia market in the upcoming years.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151456\/Key-Players-in-the-Chlamydia-Market.png\" alt=\"chlamydia companies\" class=\"wp-image-17831\" width=\"875\" height=\"245\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151456\/Key-Players-in-the-Chlamydia-Market.png 875w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151456\/Key-Players-in-the-Chlamydia-Market-300x84.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151456\/Key-Players-in-the-Chlamydia-Market-150x42.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151456\/Key-Players-in-the-Chlamydia-Market-768x215.png 768w\" sizes=\"(max-width: 875px) 100vw, 875px\" \/><figcaption><strong>Leading Companies Working in the Chlamydia Treatment Landscape<\/strong><\/figcaption><\/figure>\n\n\n\n<p>In addition, <strong>Evofem Biosciences\u2019 EVO100<\/strong> is a preventive vaginal gel that is in the late phase of development to prevent urogenital chlamydia and gonorrhea in women. The drug is intended to diminish certain vaginal infections by<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Maintaining healthy vaginal flora and establishing an environment that is unfavorable to the growth and proliferation of harmful bacteria by balancing vaginal pH.<\/li><li>Using a novel mechanism of action that could aid in addressing drug resistance concerns<\/li><\/ul>\n\n\n\n<p>The US Food and Drug Administration has granted Evofem Fast Track Designation to prevent chlamydia in women. According to the <strong>Phase IIb AMPREVENCE study<\/strong> findings, which evaluated <strong>EVO100 <\/strong>for the prevention of chlamydia and gonorrhea, the medicine met its primary and secondary goals and was generally safe and well-tolerated. The chlamydia medication is presently being tested in pivotal <strong>Phase III trials<\/strong> in women for urogenital chlamydia trachomatis and Neisseria gonorrhea infection. Top-line results are projected in 2022, with a launch date in the United States in 2023.<\/p>\n\n\n\n<p>Moreover, as per DelveInsight analysis, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-market\">chlamydia market size<\/a> was found to be over <strong>USD 50 million<\/strong> in 2021 and is expected to increase and reach up to <strong>USD 700 million<\/strong> by 2032. The rising cases of chlamydia infections present an opportunity for companies to develop therapies to prevent the disease and improve the chlamydia treatment landscape. Consequently, the focus on research and development of novel chlamydia treatments is expected to engender market growth in the coming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Expected_Roadblocks\"><\/span><strong>Expected Roadblocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Chlamydia is by far the most common <a href=\"https:\/\/www.delveinsight.com\/blog\/global-burden-of-sexually-transmitted-diseases\">sexually transmitted infection<\/a>, with a high incidence rate that is predicted to climb further in the future, needing chlamydia treatment. A considerable proportion of asymptomatic infections go undiscovered, and as a result, the chlamydia treatment market might be much bigger than expected. Furthermore, the chlamydia treatment guidelines and screening recommendations have been modified. In addition, with the emergence of incredibly sensitive and specific cost-effective testing techniques, diagnosis has become rapid and simple, driving the chlamydia treatment market even further.<\/p>\n\n\n\n<p>Moreover, a slew of <a href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-pipeline-insight\">chlamydia medicines<\/a> are in the early phases of research, including chlamydia infection blockers (CIBs), VPI-201, ABX196, and others, paving the way for the future chlamydia treatment market. Several other companies are also striving to provide novel chlamydia products.<\/p>\n\n\n\n<p>On the other hand, Doxycycline therapy is bothersome since people with GERD must sit upright for 30 minutes after each dosage. Questions have been expressed concerning azithromycin's effectiveness for concurrent rectal <em>C. trachomatis<\/em> infection, which can occur in women and cannot be predicted by reported sexual activity. Both of these limitations are constraining chlamydia treatment market expansion. Furthermore, the range of chlamydia screening procedures makes it difficult for physicians and researchers to decide which are effective, which has an impact on the growth of the chlamydia treatment market. In addition, there has been a dearth of studies relating chlamydial species to their ultimate host. As a result, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-market\">chlamydia treatment market<\/a> is seeing slow development. Furthermore, there is no consensus on the most efficient strategy for increasing chlamydia screening, which is another factor influencing the chlamydia treatment market.<\/p>\n\n\n\n<p>Furthermore, antibiotic misuse, along with patient chlamydia drug abuse, has led to an increase in antimicrobial-resistant (AMR) strains of <em>Chlamydia trachomatis<\/em>, limiting the growth of the chlamydia treatment market. Furthermore, noncompliance with recommended treatments, as well as a lack of information about chlamydia among patients and healthcare professionals, are among the important factors influencing the chlamydia treatment market growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The variety of ophthalmic, vaginal, and respiratory infections caused by Gram-negative bacteria of the genus chlamydia provide a persistent global burden and significant public health concern. Conjunctivitis and blinding trachoma are the most common diseases, followed by non-gonococcal urethritis, cervicitis, pelvic inflammatory disease, ectopic pregnancy, tubal factor infertility, and interstitial pneumonia. Failures in chlamydia screening and other preventive initiatives have led to the current medical consensus that an effective prophylactic vaccination is the best way to protect humans from chlamydial infections. Despite proven animal vaccinations, there is no <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/chlamydial-infection-newsletter\">human chlamydia vaccine<\/a>. The proper delivery of vaccine antigens to produce safe and effective immune effectors to bestow long-term protective immunity has been a major issue. The advent of biodegradable polymeric nanoparticles and adjuvanted derivatives may hasten the realization of the human vaccination dream in the near future.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/chlamydial-infection-newsletter\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook-1024x256.png\" alt=\"chlamydia treatment scenario\" class=\"wp-image-17832\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01151559\/Chlamydia-Infection-Treatment-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1656666502069\"><strong class=\"schema-faq-question\"><strong>1. What is chlamydia?<\/strong><\/strong> <p class=\"schema-faq-answer\">Chlamydia is a common sexually transmitted disease that can infect both men and women. It can permanently harm a woman's reproductive system. This can make subsequent pregnancy difficult or impossible.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1656666529696\"><strong class=\"schema-faq-question\"><strong>2. What are the chlamydia symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">The signs of chlamydia vary from person to person and gender. The common symptoms of chlamydia generally arise two to six weeks following infection.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1656666727871\"><strong class=\"schema-faq-question\"><strong>3. Does men and women have different chlamydia symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">The Chlamydia symptoms differ in men and women. The chlamydia symptoms men include pain while urinating, pain in the testicles, burning and itching in the urethra, and others. On the other hand, the Chlamydia symptoms women include vaginal discomfort and bleeding, an abnormal discharge from the vagina, pain in the pelvis, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1656666752230\"><strong class=\"schema-faq-question\"><strong>4. What is the current chlamydia treatment option?<\/strong><\/strong> <p class=\"schema-faq-answer\">Antibiotics are the only currently available chlamydia treatment option. However, there is mounting pressure to develop chlamydia vaccines with high reinfection rates.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1656666763821\"><strong class=\"schema-faq-question\"><strong>5. Which companies are developing therapies for chlamydia?<\/strong><\/strong> <p class=\"schema-faq-answer\">The leading chlamydia companies such as Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, and others are currently working in the chlamydia market.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1656666778921\"><strong class=\"schema-faq-question\"><strong>6. Which therapies are in the chlamydia pipeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">The chlamydia therapies in the pipeline include EVO100, Chlamydia infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine,\u00a0 and others.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chlamydia is the most common bacterial sexually transmitted infection across the world. Chlamydia infection is asymptomatic in 50-88% of men and women, and 46% of infections resolve spontaneously after a year. In women, persistent chlamydia infection can cause pelvic inflammatory disease, ectopic pregnancy, tubal infertility, and in men, epididymitis and epididymo-orchitis. Chlamydia infection can strike [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":17836,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19467,19471,19468,19469,19470],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-17830","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-chlamydia","tag-chlamydia-infection","tag-chlamydia-market","tag-chlamydia-treatment","tag-chlamydia-vaccine","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emerging Research Continues to Transform Chlamydia Treatment Market<\/title>\n<meta name=\"description\" content=\"Several therapies and vaccines, are at the early stage of development for chlamydia treatment. Leading companies in therapeutics market such\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerging Research Continues to Transform Chlamydia Treatment Market\" \/>\n<meta property=\"og:description\" content=\"Several therapies and vaccines, are at the early stage of development for chlamydia treatment. Leading companies in therapeutics market such\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-01T11:37:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-02T04:06:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01155748\/chlamydia-treatment-outlook.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Emerging Research Continues to Transform Chlamydia Treatment Market","description":"Several therapies and vaccines, are at the early stage of development for chlamydia treatment. Leading companies in therapeutics market such","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook","og_locale":"en_US","og_type":"article","og_title":"Emerging Research Continues to Transform Chlamydia Treatment Market","og_description":"Several therapies and vaccines, are at the early stage of development for chlamydia treatment. Leading companies in therapeutics market such","og_url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-07-01T11:37:46+00:00","article_modified_time":"2023-01-02T04:06:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01155748\/chlamydia-treatment-outlook.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook","url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook","name":"Emerging Research Continues to Transform Chlamydia Treatment Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01155748\/chlamydia-treatment-outlook.png","datePublished":"2022-07-01T11:37:46+00:00","dateModified":"2023-01-02T04:06:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Several therapies and vaccines, are at the early stage of development for chlamydia treatment. Leading companies in therapeutics market such","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666502069"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666529696"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666727871"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666752230"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666763821"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666778921"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01155748\/chlamydia-treatment-outlook.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01155748\/chlamydia-treatment-outlook.png","width":772,"height":482,"caption":"chlamydia-treatment-outlook"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666502069","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666502069","name":"1. What is chlamydia?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Chlamydia is a common sexually transmitted disease that can infect both men and women. It can permanently harm a woman's reproductive system. This can make subsequent pregnancy difficult or impossible.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666529696","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666529696","name":"2. What are the chlamydia symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The signs of chlamydia vary from person to person and gender. The common symptoms of chlamydia generally arise two to six weeks following infection.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666727871","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666727871","name":"3. Does men and women have different chlamydia symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The Chlamydia symptoms differ in men and women. The chlamydia symptoms men include pain while urinating, pain in the testicles, burning and itching in the urethra, and others. On the other hand, the Chlamydia symptoms women include vaginal discomfort and bleeding, an abnormal discharge from the vagina, pain in the pelvis, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666752230","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666752230","name":"4. What is the current chlamydia treatment option?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Antibiotics are the only currently available chlamydia treatment option. However, there is mounting pressure to develop chlamydia vaccines with high reinfection rates.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666763821","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666763821","name":"5. Which companies are developing therapies for chlamydia?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The leading chlamydia companies such as Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, and others are currently working in the chlamydia market.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666778921","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/chlamydia-treatment-outlook#faq-question-1656666778921","name":"6. Which therapies are in the chlamydia pipeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The chlamydia therapies in the pipeline include EVO100, Chlamydia infection blockers (CIBs), VPI-201, Salmonella-Based Vaccine,\u00a0 and others.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/07\/01155748\/chlamydia-treatment-outlook-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chlamydia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chlamydia infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chlamydia market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chlamydia treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chlamydia vaccine<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">chlamydia<\/span>","<span class=\"advgb-post-tax-term\">chlamydia infection<\/span>","<span class=\"advgb-post-tax-term\">chlamydia market<\/span>","<span class=\"advgb-post-tax-term\">chlamydia treatment<\/span>","<span class=\"advgb-post-tax-term\">chlamydia vaccine<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jul 1, 2022","modified":"Updated on Jan 2, 2023"},"absolute_dates_time":{"created":"Posted on Jul 1, 2022 5:07 pm","modified":"Updated on Jan 2, 2023 9:36 am"},"featured_img_caption":"chlamydia-treatment-outlook","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17830"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17830\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17836"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17830"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17830"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}